Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Purpose Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses protein kinase C
(PKC) and protein kinase B/AK transforming (AKT) signaling, induces tumor cell apoptosis …

The human epidermal growth factor receptor (EGFR) signaling is overexpressed in many
solid malignancies, making it an appealing target for biologic agents. A number of agents …

Introduction Erlotinib, a tyrosine kinase inhibitor, has improved survival and quality of life in
patients with non-small cell lung cancer (NSCLC) after first-or second-line chemotherapy …

BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

El cáncer de pulmón de células no pequeñas (CPCNP) representa aproximadamente el
75%, de todos los tumores pulmonares. Los genes comúnmente mutados en esta neoplasia …

Abstract Treatment of non-small-cell lung cancer is dependent on disease stage. For
patients with metastasis or locally advanced disease, the importance of finding therapeutic …

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death in
both men and women in most of the Western world, with an estimated 900,000 deaths per …